The Korean journal of internal medicine

  • 제29권1호
  • /
  • Pages.132-147
  • /
  • 2014
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Severe influenza treatment guideline

  • Choi, Won Suk (Department of Internal Medicine, Korea University College of Medicine) ;
  • Baek, Ji Hyeon (Department of Internal Medicine, Inha University School of Medicine) ;
  • Seo, Yu Bin (Department of Internal Medicine, Hallym University College of Medicine) ;
  • Kee, Sae Yoon (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Jeong, Hye Won (Department of Internal Medicine, Chungbuk National University College of Medicine) ;
  • Lee, Hee Young (Gachon University Gil Hospital Cancer Center, Gachon University Gil Medical Center) ;
  • Eun, Byung Wook (Department of Pediatrics, Eulji University School of Medicine) ;
  • Choo, Eun Ju (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Lee, Jacob (Department of Internal Medicine, Hallym University College of Medicine) ;
  • Kim, Young Keun (Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
  • Song, Joon Young (Department of Internal Medicine, Korea University College of Medicine) ;
  • Wie, Seong-Heon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Jin Soo (Department of Internal Medicine, Inha University School of Medicine) ;
  • Cheong, Hee Jin (Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Woo Joo (Department of Internal Medicine, Korea University College of Medicine) ;
  • Transgovernmental Enterprise for Pandemic Influenza in Korea (Transgovernmental Enterprise for Pandemic Influenza in Korea)
  • 투고 : 2013.12.12
  • 심사 : 2013.12.17
  • 발행 : 2014.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Choi WS, Lee J, Lee HY, et al. Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza. Infect Chemother 2012;44:233-249. https://doi.org/10.3947/ic.2012.44.4.233
  2. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses [Internet]. Geneva (CH): World Health Organization, c2013 [cited 2013 Oct 2]. Available from: http://www.who.int/csr/resources/publications/swinef lu/h1n1_use_antivirals_20090820/en/.
  3. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-1246. https://doi.org/10.1001/jama.282.13.1240
  4. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of inf luenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011;55:2803-2812. https://doi.org/10.1128/AAC.01718-10
  5. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute inf luenza: a randomised controlled trial: Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-1850. https://doi.org/10.1016/S0140-6736(00)02288-1
  6. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial: US Oral Neuraminidase Study Group. JAMA 2000;283:1016-1024. https://doi.org/10.1001/jama.283.8.1016
  7. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 2012;7:e29652. https://doi.org/10.1371/journal.pone.0029652
  8. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013;346:f3039. https://doi.org/10.1136/bmj.f3039
  9. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013;57:1511-1519. https://doi.org/10.1093/cid/cit597
  10. Kim AR, Kim ES, Pai KS, Park JE. A case of high dose oseltamivir treatment in an influenza A (H1N1) infected patient with severe graft versus host disease. Clin Pediatr Hematol Oncol 2011;18:58-61.
  11. Kang SJ, Park KH, Kee SJ, et al. Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection. Jpn J Infect Dis 2013;66:425-427. https://doi.org/10.7883/yoken.66.425
  12. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of inf luenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007;28:1071-1076. https://doi.org/10.1086/520101
  13. Fiore AE; United States Advisory Committee on Immunization Practices; National Center for Immunization and Respiratory Diseases (US); National Center for Immunization and Respiratory Diseases (US) Influenza Division; Centers for Disease Control and Prevention (US). Antiviral Agents for the Treatment and Chemoprophylaxis of Inf luenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Atlanta: US Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2011.
  14. Escuret V, Cornu C, Boutitie F, et al. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A (H1N1) virus infections. Antiviral Res 2012;96:130-137. https://doi.org/10.1016/j.antiviral.2012.08.002
  15. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo- controlled trial. PLoS Med 2010;7:e1000362. https://doi.org/10.1371/journal.pmed.1000362
  16. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009;53:2120-2128. https://doi.org/10.1128/AAC.01012-08
  17. Nguyen JT, Hoopes JD, Smee DF, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009;53:4115-4126. https://doi.org/10.1128/AAC.00476-09
  18. Kim WY, Young Suh G, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011;55:5703-5709. https://doi.org/10.1128/AAC.05529-11
  19. Fraaij PL, van der Vries E, Beersma MF, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic inf luenza A (H1N1) infection. J Infect Dis 2011;204:777-782. https://doi.org/10.1093/infdis/jir397
  20. Petersen E, Keld DB, Ellermann-Eriksen S, et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011;43:495-503. https://doi.org/10.3109/00365548.2011.556144
  21. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2004;2:CD000023.
  22. Smucny J, Fahey T, Becker L, Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2004;4:CD000245.
  23. Spurling GK, Del Mar CB, Dooley L, Foxlee R, Farley R. Delayed antibiotics for respiratory infections. Cochrane Database Syst Rev 2013;4:CD004417.
  24. Morciano C, Vitale A, De Masi S, et al. Italian evidence- based guidelines for the management of influenza-like syndrome in adults and children. Ann Ist Super Sanita 2009;45:185-192.
  25. Centers for Disease Control and Prevention (CDC). Surveillance for pediatric deaths associated with 2009 pandemic inf luenza A (H1N1) virus infection: United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009;58:941-947.
  26. Wright PF, Kirkland KB, Modlin JF. When to consider the use of antibiotics in the treatment of 2009 H1N1 inf luenza-associated pneumonia. N Engl J Med 2009;361:e112. https://doi.org/10.1056/NEJMopv0910749
  27. Song JH, Jung KS, Kang MW, et al. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. Infect Chemother 2009;41:133-153. https://doi.org/10.3947/ic.2009.41.3.133
  28. Korean Otologic Society. Korean Clinical Practice Guideline: Otitis Media in Children 2010. Seoul: Korean Otologic Society, 2010.
  29. Paden ML, Conrad SA, Rycus PT, Thiagarajan RR; ELSO Registry. Extracorporeal life support organization registry report 2012. ASAIO J 2013;59:202-210. https://doi.org/10.1097/MAT.0b013e3182904a52
  30. Sadahiro T, Oda S, Nakamura M, et al. Trends in and perspectives on extracorporeal membrane oxygenation for severe adult respiratory failure. Gen Thorac Cardiovasc Surg 2012;60:192-201. https://doi.org/10.1007/s11748-011-0868-z
  31. Rodriguez A, Alvarez-Rocha L, Sirvent JM, et al. Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of inf luenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit. Med Intensiva 2012;36:103-137. https://doi.org/10.1016/j.medin.2011.11.020
  32. Michaels AJ, Hill JG, Bliss D, et al. Pandemic flu and the sudden demand for ECMO resources: a mature trauma program can provide surge capacity in acute critical care crises. J Trauma Acute Care Surg 2013;74:1493-1497. https://doi.org/10.1097/TA.0b013e31828d636e
  33. Zangrillo A, Biondi-Zoccai G, Landoni G, et al. Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO. Crit Care 2013;17:R30. https://doi.org/10.1186/cc12512
  34. Pappalardo F, Pieri M, Greco T, et al. Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to inf luenza A (H1N1) pneumonia: the ECMOnet score. Intensive Care Med 2013;39:275-281. https://doi.org/10.1007/s00134-012-2747-1
  35. Takeda S, Kotani T, Nakagawa S, et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) severe respiratory failure in Japan. J Anesth 2012;26:650-657. https://doi.org/10.1007/s00540-012-1402-x
  36. Roncon-Albuquerque R Jr, Basilio C, Figueiredo P, et al. Portable miniaturized extracorporeal membrane oxygenation systems for H1N1-related severe acute respiratory distress syndrome: a case series. J Crit Care 2012;27:454-463. https://doi.org/10.1016/j.jcrc.2012.01.008
  37. Brink M, Hagberg L, Larsson A, Gedeborg R. Respiratory support during the influenza A (H1N1) pandemic flu in Sweden. Acta Anaesthesiol Scand 2012;56:976-986. https://doi.org/10.1111/j.1399-6576.2012.02727.x
  38. Hou X, Guo L, Zhan Q, et al. Extracorporeal membrane oxygenation for critically ill patients with 2009 influenza A (H1N1)-related acute respiratory distress syndrome: preliminary experience from a single center. Artif Organs 2012;36:780-786. https://doi.org/10.1111/j.1525-1594.2012.01468.x
  39. Shetty AK, Ross GA, Pranikoff T, et al. Oseltamivir-resistant 2009 H1N1 inf luenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant 2012;16:E153-E157. https://doi.org/10.1111/j.1399-3046.2011.01489.x
  40. Sohn JW. Critical care paper review 2012. Tuberc Respir Dis (Seoul) 2012;73:1-10. https://doi.org/10.4046/trd.2012.73.1.1
  41. Morgan CI, Hobson MJ, Seger B, Rice MA, Staat MA, Wheeler DS. 2009 pandemic influenza A (H1N1) in critically ill children in Cincinnati, Ohio. Pediatr Crit Care Med 2012;13:e140-e144. https://doi.org/10.1097/PCC.0b013e318228845f
  42. Bonastre J, Suberviola B, Pozo JC, et al. Extracorporeal lung support in patients with severe respiratory failure secondary to the 2010-2011 winter seasonal outbreak of influenza A (H1N1) in Spain. Med Intensiva 2012;36:193-199. https://doi.org/10.1016/j.medin.2011.12.004
  43. Lemaitre F, Luyt CE, Roullet-Renoleau F, et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) inf luenza. Ther Drug Monit 2012;34:171-175. https://doi.org/10.1097/FTD.0b013e318248672c
  44. Beurtheret S, Mastroianni C, Pozzi M, et al. Extracorporeal membrane oxygenation for 2009 inf luenza A (H1N1) acute respiratory distress syndrome: single-centre experience with 1-year follow-up. Eur J Cardiothorac Surg 2012;41:691-695. https://doi.org/10.1093/ejcts/ezr082
  45. Azevedo LC, Park M, Costa EL, et al. Extracorporeal membrane oxygenation in severe hypoxemia: time for reappraisal? J Bras Pneumol 2012;38:7-12. https://doi.org/10.1590/S1806-37132012000100003
  46. Li HL, Meng C, Zhu X, Guo LM, Li BS. The application of extracorporeal membrane oxygenation in critically ill patient. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012;24:86-89.
  47. van Ierssel SH, Leven M, Jorens PG. Severe influenza A (H1N1) 2009 infection: a single centre experience and review of the literature. Acta Clin Belg 2012;67:1-6.
  48. Ji S, Lee OJ, Yang JH, et al. 2009 H1N1 influenza virus infection and necrotizing pneumonia treated with extracorporeal membrane oxygenation. Korean J Pediatr 2011;54:345-349. https://doi.org/10.3345/kjp.2011.54.8.345
  49. Lee KH, Yie K, Oh WS, Ryu SW, Chon SB, Lee SJ. Early extracorporeal membrane oxygenation in a patient with pandemic influenza (H1N1 2009) and acute respiratory distress syndrome. Infect Chemother 2010;42:122-126.
  50. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009;302:1880-1887. https://doi.org/10.1001/jama.2009.1536
  51. Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010;36:33-41. https://doi.org/10.1007/s00134-009-1727-6
  52. Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH. Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 inf luenza virus. Crit Care 2011;15:413. https://doi.org/10.1186/cc10082
  53. Sohn YR, Kim JH, Ma SH, Lee KY, Kang JH. Severe pneumonia caused by 2009 pandemic inf luenza A (H1N1) virus in children and corticosteroid treatment. Korean J Pediatr Infect Dis 2011;18:193-200.
  54. Confalonieri M, D'Agaro P, Campello C. Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection. Intensive Care Med 2010;36:1780-1781. https://doi.org/10.1007/s00134-010-1964-8
  55. Confalonieri M, Cifaldi R, Dreas L, Viviani M, Biolo M, Gabrielli M. Methylprednisolone infusion for life-threatening H1N1-virus infection. Ther Adv Respir Dis 2010;4:233-237. https://doi.org/10.1177/1753465810376951
  56. Ohtsuki N, Kimura S, Nezu A, Aihara Y. Effects of mild hypothermia and steroid pulse combination therapy on acute encephalopathy associated with inf luenza virus infection: report of two cases. No To Hattatsu 2000;32:318-322.
  57. Hibino M, Akazawa K, Hikino K, Oe M. A case of acute respiratory distress syndrome associated with pandemic influenza A (H1N1) pneumonia which was aggravated by the cessation of corticosteroid therapy. Nihon Kokyuki Gakkai Zasshi 2011;49:955-963.
  58. Samejima T, Takayanagi N, Ishiguro T, Miyahara Y, Yanagisawa T, Sugita Y. Case of novel influenza A (H1N1) pneumonia with shrinkage of a pulmonary lesion. Nihon Kokyuki Gakkai Zasshi 2010;48:930-937.
  59. Ishiguro T, Takayanagi N, Kanauchi T, Hoshi T, Yanagisawa T, Sugita Y. Two patients with novel influenza A virus (H1N1) pneumonia treated with steroid therapy after an incorrect diagnosis of rapid progressive interstitial pneumonia due to the negative results of a rapid-antigen test. Nihon Kokyuki Gakkai Zasshi 2010;48:687-695.
  60. Sakurai T, Kimura A, Tanaka Y, Hozumi I, Ogura S, Inuzuka T. Case of adult influenza type A virus-associated encephalopathy successfully treated with primary multidisciplinary treatments. Rinsho Shinkeigaku 2007;47:639-643.
  61. Djibre M, Berkane N, Salengro A, et al. Non-invasive management of acute respiratory distress syndrome related to Influenza A (H1N1) virus pneumonia in a pregnant woman. Intensive Care Med 2010;36:373-374. https://doi.org/10.1007/s00134-009-1684-0
  62. Ando M, Miyazaki E, Hiroshige S, et al. Virus associated hemophagocytic syndrome accompanied by acute respiratory failure caused by influenza A (H3N2). Intern Med 2006;45:1183-1186. https://doi.org/10.2169/internalmedicine.45.1736
  63. Athauda D, Andrews TC, Holmes PA, Howard RS. Multiphasic acute disseminated encephalomyelitis (ADEM) following influenza type A (swine specific H1N1). J Neurol 2012;259:775-778. https://doi.org/10.1007/s00415-011-6258-8
  64. Wang Y, Lu YY, Zheng J, Da W, Ping C, Da DZ. Treatment of critically ill influenza A H1N1 patients in plateau region. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2010;22:153-155.
  65. Kawashima H, Togashi T, Yamanaka G, et al. Efficacy of plasma exchange and methylprednisolone pulse therapy on inf luenza-associated encephalopathy. J Infect 2005;51:E53-E56. https://doi.org/10.1016/j.jinf.2004.08.017
  66. Munakata M, Kato R, Yokoyama H, et al. Combined therapy with hypothermia and anticytokine agents in influenza A encephalopathy. Brain Dev 2000;22:373-377. https://doi.org/10.1016/S0387-7604(00)00169-8
  67. Roberts C, Nirmalan M, O'Shea S. Steroid-sensitive post-viral inflammatory pneumonitis (PVIP). Am J Respir Crit Care Med 2010;182:1089-1090.
  68. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1) v influenza A infection. Intensive Care Med 2011;37:272-283. https://doi.org/10.1007/s00134-010-2078-z
  69. Mady A, Ramadan OS, Yousef A, Mandourah Y, Amr AA, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. J Infect Public Health 2012;5:52-56. https://doi.org/10.1016/j.jiph.2011.10.005
  70. Linko R, Pettila V, Ruokonen E, et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed inf luenza A (H1N1) infection in Finland. Acta Anaesthesiol Scand 2011;55:971-979. https://doi.org/10.1111/j.1399-6576.2011.02491.x
  71. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011;53:326-333. https://doi.org/10.1093/cid/cir398
  72. Maravi-Poma E, Martin-Loeches I, Regidor E, et al. Severe 2009 A/H1N1v influenza in pregnant women in Spain. Crit Care Med 2011;39:945-951. https://doi.org/10.1097/CCM.0b013e318208ee12
  73. Kawashima H, Morichi S, Okumara A, Nakagawa S, Morishima T; Collaborating Study Group on Inf luenza- Associated Encephalopathy in Japan. Treatment of pandemic influenza A (H1N1) 2009-associated encephalopathy in children. Scand J Infect Dis 2012;44:941-947. https://doi.org/10.3109/00365548.2012.700769
  74. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L; REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011;183:1200-1206. https://doi.org/10.1164/rccm.201101-0135OC
  75. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011;183:1207-1214. https://doi.org/10.1164/rccm.201101-0110OC
  76. Diaz E, Martin-Loeches I, Canadell L, et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012;64:311-318. https://doi.org/10.1016/j.jinf.2011.12.010
  77. Chong JL, Sapari S, Kuan YC. A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect 2011;44:319-322. https://doi.org/10.1016/j.jmii.2010.07.001
  78. Gordon CL, Langan K, Charles PG, et al. Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 inf luenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin Infect Dis 2011;52:422-426.
  79. Iwanaga N, Nakamura S, Tanaka A, et al. An adult case of influenza-associated encephalitis successfully treated with high dose intravenous immunoglobulins. Kansenshogaku Zasshi 2012;86:295-299. https://doi.org/10.11150/kansenshogakuzasshi.86.295
  80. Zhang R, Jin L, Jin M, et al. Clinical analysis of children with lymphoma complicated with severe pneumonia due to novel influenza A (H1N1) virus infection. Zhonghua Er Ke Za Zhi 2010;48:610-613.
  81. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-368. https://doi.org/10.1016/S1473-3099(07)70111-1
  82. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012;205:13-19. https://doi.org/10.1093/infdis/jir695
  83. Kwong JC, Li P, Redelmeier DA. Inf luenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 2009;4:e8087. https://doi.org/10.1371/journal.pone.0008087
  84. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-1012. https://doi.org/10.1378/chest.06-1997
  85. Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A (H1N1) disease. PLoS One 2011;6:e18120. https://doi.org/10.1371/journal.pone.0018120
  86. Carrillo-Esper R, Sosa-Garcia JO, Arch-Tirado E. Experience in the management of the severe form of human influenza A H1N1 pneumonia in an intensive care unit. Cir Cir 2011;79:409-416.
  87. Viasus D, Pano-Pardo JR, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011;62:193-199. https://doi.org/10.1016/j.jinf.2011.01.014
  88. Patel P, Nandwani V, Vanchiere J, Conrad SA, Scott LK. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 inf luenza A: an associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med 2011;12:e87-e89. https://doi.org/10.1097/PCC.0b013e3181e2a569

피인용 문헌

  1. Antiviral treatment of influenza in South Korea vol.13, pp.6, 2014, https://doi.org/10.1586/14787210.2015.1032253
  2. Invasive Pulmonary Aspergillosis after Recent Influenza in a Child with Acute Myeloid Leukemia vol.22, pp.2, 2014, https://doi.org/10.15264/cpho.2015.22.2.190
  3. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives vol.13, pp.11, 2014, https://doi.org/10.1586/14787210.2015.1076334
  4. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis vol.19, pp.None, 2015, https://doi.org/10.1186/s13054-015-0764-5
  5. Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection vol.6, pp.None, 2014, https://doi.org/10.1038/srep29154
  6. Influenza vol.92, pp.6, 2014, https://doi.org/10.3904/kjm.2017.92.6.494
  7. Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies? vol.14, pp.3, 2014, https://doi.org/10.1080/21645515.2017.1363135
  8. Effects of influenza immunization on pneumonia in the elderly vol.14, pp.3, 2014, https://doi.org/10.1080/21645515.2017.1405200
  9. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea vol.33, pp.2, 2014, https://doi.org/10.3904/kjim.2018.036
  10. Poor outcomes among elderly patients hospitalized for influenza-like illness vol.34, pp.7, 2014, https://doi.org/10.1080/03007995.2017.1381078
  11. Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection vol.218, pp.9, 2018, https://doi.org/10.1093/infdis/jiy328
  12. Comparison of Clinical Characteristics for Distinguishing COVID-19 From Influenza During the Early Stages in Guangdong, China vol.8, pp.None, 2014, https://doi.org/10.3389/fmed.2021.733999
  13. Influenza infection, SARS, MERS and COVID-19: Cytokine storm – The common denominator and the lessons to be learned vol.223, pp.None, 2014, https://doi.org/10.1016/j.clim.2020.108652
  14. Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization vol.87, pp.3, 2014, https://doi.org/10.1111/bcp.14523